目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Tumor Type
1.1.2. Model Type
1.1.3. End User
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.9.3. Objective 3
1.9.4. Objective 4

Chapter 2. Executive Summary
2.1. Market Outlook

Chapter 3. Patient-Derived Xenograft Model Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Growing burden of cancer across the globe
3.3.1.2. Increasing R&D investment for cancer research
3.3.1.3. Demand for personalized therapies worldwide
3.3.2. Market restraint analysis
3.3.2.1. High cost of personalized PDX models
3.3.2.2. Stringent regulations towards the use of animal models
3.3.3. Penetration & Growth Prospect Mapping
3.3.4. Covid-19 Impact & Recovery Analysis
3.3.5. Major Deals and Strategic Alliances Analysis
3.3.6. Industry Analysis - Porter’s
3.3.7. PESTLE Analysis

Chapter 4. Patient-Derived Xenograft Model Market: Tumor Type Segment Analysis
4.1. Patient-Derived Xenograft Model Market: Definition & Scope
4.2. Patient-Derived Xenograft Model Market: Tumor Type Market Share Analysis, 2021 & 2030
4.2.1. Lung Cancer
4.2.1.1. Lung Cancer Market, 2018 - 2030 (USD Million)
4.2.2. Pancreatic Cancer
4.2.2.1. Pancreatic Cancer Market, 2018 - 2030 (USD Million)
4.2.3. Prostate Cancer
4.2.3.1. Prostate Cancer Market, 2018 - 2030 (USD Million)
4.2.4. Breast Cancer
4.2.4.1. Breast Cancer Market, 2018 - 2030 (USD Million)
4.2.5. Other Cancer
4.2.5.1. Other Cancer Market, 2018 - 2030 (USD Million)

Chapter 5. Patient-Derived Xenograft Model Market: Model Type Segment Analysis
5.1. Patient-Derived Xenograft Model Market: Definition & Scope
5.2. Patient-Derived Xenograft Model Market: Model Type Market Share Analysis, 2021 & 2030
5.2.1. Mice
5.2.1.1. Mice Market, 2018 - 2030 (USD Million)
5.2.2. Rats
5.2.2.1. Rats Market, 2018 - 2030 (USD Million)

Chapter 6. Patient-Derived Xenograft Model Market: End-user Segment Analysis
6.1. Patient-Derived Xenograft Model Market: Definition & Scope
6.2. Patient-Derived Xenograft Model Market: End User Market Share Analysis, 2021 & 2030
6.2.1. Pharmaceutical & Biopharmaceutical Companies
6.2.1.1. Pharmaceutical & Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)
6.2.2. Academic & Research Institutes
6.2.2.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
6.2.3. CROs & CDMOs
6.2.3.1. CROs & CDMOs Market, 2018 - 2030 (USD Million)

Chapter 7. Patient-Derived Xenograft Model Market: Regional Analysis
7.1. Patient-Derived Xenograft Model: Regional market share analysis, 2021 & 2030
7.2. North America
7.2.1. U.S. Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
7.3.2. U.K.
7.3.2.1. U.K. Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
7.3.4. Italy
7.3.4.1. Italy Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
7.3.5. Spain
7.3.5.1. Spain Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
7.3.6. France
7.3.6.1. France Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
7.4.2. China
7.4.2.1. China Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
7.4.3. India
7.4.3.1. India Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
7.4.4. Japan
7.4.4.1. Japan Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
7.4.5. Australia
7.4.5.1. Australia Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
7.5. Latin America
7.5.1. Latin America Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Mexico Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Argentina Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. MEA Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
7.6.3. South Arabia
7.6.3.1. South Africa Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Patient-Derived Xenograft Model: Company market share analysis, 2021 & 2030
8.2. Company Profiles
8.2.1. Charles River Laboratories
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Service benchmarking
8.2.1.4. Strategic initiatives
8.2.2. The Jackson Laboratory
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Service benchmarking
8.2.2.4. Strategic initiatives
8.2.3. Crown Bioscience
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Service benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Altogen Labs
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Service benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Envigo
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Service benchmarking
8.2.5.4. Strategic initiatives
8.2.6. WuxiAppTec
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Service benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Oncodesign
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Service benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Hera Biolabs
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Service benchmarking
8.2.8.4. Strategic initiatives
8.2.9. XenTech
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Service benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Abnova Corporation
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Service benchmarking
8.2.10.4. Strategic initiatives

List of Tables
Table 1 List of Secondary sources
Table 2 List of Abbreviations

List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Volume price analysis
Fig. 9 Patient-derived xenograft model market snapshot (2021)
Fig. 10 Patient-derived xenograft model market segmentation
Fig. 11 Heat map analysis
Fig. 12 Parent market outlook
Fig. 13 Ancillary market outlook
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Market driver relevance analysis (Current & future impact)
Fig. 16 Market restraint relevance analysis (Current & future impact)
Fig. 17 Porter’s five forces analysis
Fig. 18 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 19 Patient-derived xenograft model market tumor type outlook: Segment dashboard
Fig. 20 Patient-derived xenograft model market: tumor type movement analysis
Fig. 21 Lung cancer market, 2018 - 2030 (USD Million)
Fig. 22 Pancreatic cancer market, 2018 - 2030 (USD Million)
Fig. 23 Prostate cancer market, 2018 - 2030 (USD Million)
Fig. 24 Breast cancer market, 2018 - 2030 (USD Million)
Fig. 25 Other cancer market, 2018 - 2030 (USD Million)
Fig. 26 Patient-derived xenograft model market model type outlook: Segment dashboard
Fig. 27 Patient-derived xenograft model market: model type movement analysis
Fig. 28 Mice market, 2018 - 2030 (USD Million)
Fig. 29 Rats market, 2018 - 2030 (USD Million)
Fig. 30 Patient-derived xenograft model market end-user outlook: Segment dashboard
Fig. 31 Patient-derived xenograft model market: End user movement analysis
Fig. 32 Pharmaceutical & Biopharmaceutical companies market, 2018 - 2030 (USD Million)
Fig. 33 Academic & research institutes market, 2018 - 2030 (USD Million)
Fig. 34 CROs & CDMOs market, 2018 - 2030 (USD Million)
Fig. 35 Regional market: Key takeaways
Fig. 36 Patient-derived xenograft model market: Regional movement analysis
Fig. 37 North America. market, 2018 - 2030 (USD Million)
Fig. 38 U.S. market, 2018 - 2030 (USD Million)
Fig. 39 Canada market, 2018 - 2030 (USD Million)
Fig. 40 Europe market, 2018 - 2030 (USD Million)
Fig. 41 U.K. market, 2018 - 2030 (USD Million)
Fig. 42 Germany market, 2018 - 2030 (USD Million)
Fig. 43 France market, 2018 - 2030 (USD Million)
Fig. 44 Italy market, 2018 - 2030 (USD Million)
Fig. 45 Spain market, 2018 - 2030 (USD Million)
Fig. 46 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 47 Japan market, 2018 - 2030 (USD Million)
Fig. 48 China market, 2018 - 2030 (USD Million)
Fig. 49 India market, 2018 - 2030 (USD Million)
Fig. 50 Australia market, 2018 - 2030 (USD Million)
Fig. 51 Latin America market, 2018 - 2030 (USD Million)
Fig. 52 Brazil market, 2018 - 2030 (USD Million)
Fig. 53 Mexico market, 2018 - 2030 (USD Million)
Fig. 54 Argentina market, 2018 - 2030 (USD Million)
Fig. 55 MEA market, 2018 - 2030 (USD Million)
Fig. 56 South Africa market, 2018 - 2030 (USD Million)
Fig. 57 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 58 UAE market, 2018 - 2030 (USD Million)